

sociations for rs478333 and rs7754840 remained significant after adjustment for conventional risk factors.

The three implicated gene variants seem to be novel predictors of CKD associated with type 2 diabetes in a Chinese population. Jian et al. believe that their three-step process may be useful for selecting predictors of clinical outcomes in other large datasets including clinical and genetic data [Jian G, et al. Genetic and clinical variables identify predictors for chronic kidney disease in type 2 diabetes. *Kidney Int* 2016; 89:411–420]. ●

## Adding insulin to metformin increases hypoglycemia risk

For diabetic patients on metformin who require treatment intensification, adding insulin rather than sulfonylurea is associated with an increased risk of hypoglycemia, reports a study in the *Canadian Medical Association Journal*.

Using the Veterans Health Administration database, the researchers identified 178,341 patients who initiated metformin treatment between 2001 and 2008. Treatment was subsequently intensified using insulin in 2948 patients and sulfonylurea in 39,990 patients. Risk of a first or recurrent hypoglycemia event was

compared in propensity score-matched groups: 2436 patients taking metformin plus insulin versus 12,180 patients taking metformin plus sulfonylurea.

At the time of treatment intensification, patients had been taking metformin for a median of 14 months and had a median glycosylated hemoglobin level of 8.1 percent. The follow-up data included 121 first hypoglycemic events among patients who added insulin and 466 first hypoglycemic events among patients who added sulfonylurea. Outcome rates were 30.9 versus 24.6 events per 1000 person-years,

respectively—adjusted hazard ratio was 1.30 with insulin compared with sulfonylurea.

Insulin intensification was also associated with a higher rate of recurrent hypoglycemia: 39.1 versus 30.0 per 1000 person-years (hazard ratio of 1.39). Accounting for competing risk of death, the hazard ratio for initial hypoglycemia in the insulin group was 1.28 [Roumie CL, et al. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. *CMAJ* 2016; doi:10.1503/cmaj.150904]. ●

**IMPROVED FORMULARY ACCESS!**  
Visit [Auryxia.com](http://Auryxia.com) to learn more

For the control of serum phosphorus levels in patients with chronic kidney disease on dialysis

## AURYXIA™ (ferric citrate) IS THE FIRST AND ONLY ABSORBABLE-IRON–BASED PHOSPHATE BINDER CLINICALLY PROVEN TO MANAGE HYPERPHOSPHATEMIA<sup>1-6</sup>

- Proven control of serum phosphorus within KDOQI guidelines (4.88 mg/dL at Week 56)<sup>7,8</sup>
- Demonstrated safety and tolerability profile over 52 weeks
- Each AURYXIA tablet contains 210 mg ferric iron, equivalent to 1 g ferric citrate

**Auryxia™**  
(ferric citrate) tablets

### References:

1. Fosrenol [package insert]. Wayne, PA: Shire US, Inc.; 2014. 2. Phoslyra [package insert]. Waltham, MA: Fresenius Medical Care North America; 2011. 3. PhosLo Gelcaps [package insert]. Waltham, MA: Fresenius Medical Care North America; 2012. 4. Renagel [package insert]. Cambridge, MA: Genzyme Corporation; 2015. 5. Renvela [package insert]. Cambridge, MA: Genzyme Corporation; 2015. 6. Velphoro [package insert]. Waltham, MA: Fresenius Medical Care North America; 2014. 7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis*. 2003;42(4 Suppl 3):S1-S201. 8. Data on File 1, Keryx Biopharmaceuticals, Inc.

a risk for spontaneous abortion, gestational diabetes, and fetal malformation. Rat studies have shown the transfer of iron into milk. There is possible infant exposure when AURYXIA is taken by a nursing woman.

**Pediatric:** The safety and efficacy of AURYXIA have not been established in pediatric patients.

**Adverse Events:** The most common adverse events with AURYXIA were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%), and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing AURYXIA (14%).

**Drug Interactions:** Doxycycline should be taken at least 1 hour before AURYXIA. Ciprofloxacin should be taken at least 2 hours before or after AURYXIA. Consider separation of the timing of the administration of AURYXIA with drugs where a reduction in their bioavailability would have a clinically significant effect on safety or efficacy.

Please see Brief Summary on following page.

You may report side effects to Keryx at 1-844-44KERYX (844-445-3799).



©2015 Keryx Biopharmaceuticals, Inc.  
PP-AUR-US-0173 08/15